Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation

Biochemical Pharmacology

Volumn 82, Issue 5, 2011, Pages 524-534

  Yang, Hee Jung ^a   Youn, HyeSook ^b   Seong, Ki Moon ^c   Yun, Young Ju ^a   Kim, Wanyeon ^a   Kim, Young Ha ^a   Lee, Ji Young ^a   Kim, Cha Soon ^c   Jin, Young Woo ^c   Youn, BuHyun ^a  

^a Pusan National University   (South Korea)

^b Sejong University   (South Korea)

^c Korea Hydro & Nuclear Power Co   (South Korea)

Author keywords

5 LOX; Anti inflammation; COX 2; Ionizing radiation; Psoralidin

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; PSORALIDIN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL MIGRATION; CELL STRAIN; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG FIBROBLAST; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION PROTECTION;

5-LIPOXYGENASE-ACTIVATING PROTEINS; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BENZOFURANS; CELLS, CULTURED; COUMARINS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LIPOXYGENASE INHIBITORS; LUNG; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PNEUMONIA; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-PROTECTIVE AGENTS;

EID: 79960910603     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.05.027     Document Type: Article

References (58)

1. Goodman GE. Lung cancer. 1: prevention of lung cancer. Thorax 2002;57: 994-9.
2. Baumann M, Krause M, Zips D, Petersen C, Dittmann K, Dorr W, et al. Molecular targeting in radiotherapy of lung cancer. Lung Cancer 2004;45(Suppl. 2): S187-97. (Pubitemid 39488188)
3. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer 2005;5:867-75.
4. Schmidt-Ullrich RK, Dent P, Grant S, Mikkelsen RB, Valerie K. Signal transduction and cellular radiation responses. Radiat Res 2000;153:245-57. (Pubitemid 30224838)
5. Molla M, Panes J. Radiation-induced intestinal inflammation. World J Gastroenterol 2007;13:3043-6. (Pubitemid 47045460)
6. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. (Pubitemid 36019639)
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
8. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78. (Pubitemid 30155608)
9. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 2003;95:1440-52. (Pubitemid 37279329)
10. Murphy RC, Gijon MA. Biosynthesis and metabolism of leukotrienes. Biochem J 2007;405:379-95. (Pubitemid 47172035)
11. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007;82:85-94. (Pubitemid 44895440)
12. Mandal AK, Skoch J, Bacskai BJ, Hyman BT, Christmas P, Miller D, et al. The membrane organization of leukotriene synthesis. Proc Natl Acad Sci USA 2004;101:6587-92. (Pubitemid 38586018)
13. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72-8.
14. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol Pharmacol 2006;57(Suppl. 5):113-24. (Pubitemid 46569788)
15. Reddy RC, Chen GH, Tateda K, Tsai WC, Phare SM, Mancuso P, et al. Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am J Physiol Lung Cell Mol Physiol 2001;281:L537-43.
16. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8.
17. Charlier C, Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal antiinflammatory drugs. Eur J Med Chem 2003;38:645-59. (Pubitemid 36980661)
18. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal antiinflammatory drugs. Ann Rheum Dis 2003;62:501-9. (Pubitemid 36606279)
19. Schmidt B, Ribnicky DM, Poulev A, Logendra S, Cefalu WT, Raskin I. A natural history of botanical therapeutics. Metabolism 2008;57:S3-9. (Pubitemid 351814695)
20. Zhao L, Huang C, Shan Z, Xiang B, Mei L. Fingerprint analysis of Psoralea corylifolia L. by HPLC and LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2005;821:67-74. (Pubitemid 40779587)
21. Kim YC, Oh H, Kim BS, Kang TH, Ko EK, Han YM, et al. In vitro protein tyrosine phosphatase 1B inhibitory phenols from the seeds of Psoralea corylifolia. Planta Med 2005;71:87-9. (Pubitemid 40223360)
22. Chen Y, Cheung YT, Kong LD, Ng TB, Qiao C, Mo SF, et al. Transcriptional regulation of corticotrophin releasing factor gene by furocoumarins isolated from seeds of Psoralea corylifolia. Life Sci 2008;82:1117-21.
23. Matsuda H, Sugimoto S, Morikawa T, Matsuhira K, Mizuguchi E, Nakamura S, et al. Bioactive constituents from Chinese natural medicines. XX. Inhibitors of antigen-induced degranulation in RBL-2H3 cells from the seeds of Psoralea corylifolia. Chem Pharm Bull (Tokyo) 2007;55:106-10. (Pubitemid 46067592)
24. Kim W, Yang HJ, Youn H, Yun YJ, Seong KM, Youn B. Myricetin inhibits Akt survival signaling and induces Bad-mediated apoptosis in a low dose ultraviolet (UV)-B-irradiated HaCaT human immortalized keratinocytes. J Radiat Res (Tokyo) 2010;51:285-96.
25. Kim TS, Kim HD, Kim J. PKCdelta-dependent functional switch of rpS3 between translation and DNA repair. Biochim Biophys Acta 2009;1793:395-405.
26. Lee KW, Kang NJ, Rogozin EA, Kim HG, Cho YY, Bode AM, et al. Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis 2007;28:1918-27. (Pubitemid 47500604)
27. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007;317:510-2. (Pubitemid 47196114)
28. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 2009;16:130-43.
29. Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 2001;23:99-109. (Pubitemid 32575352)
30. Kim JH, Na HK, Pak YK, Lee YS, Lee SJ, Moon A, et al. Roles of ERK and p38 mitogen-activated protein kinases in phorbol ester-induced NF-kappaB activation and COX-2 expression in human breast epithelial cells. Chem Biol Interact 2008;171:133-41.
31. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11. (Pubitemid 32047405)
32. Makarov SS. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 2000;6:441-8.
33. Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB. NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation. J Biol Chem 2005;280:21400-8. (Pubitemid 40805704)
34. Ishii-Yonemoto T, Masuzaki H, Yasue S, Okada S, Kozuka C, Tanaka T, et al. Glucocorticoid reamplification within cells intensifies NF-kappaB and MAPK signaling and reinforces inflammation in activated preadipocytes. Am J Physiol Endocrinol Metab 2010;298:E930-40.
35. Vickers PJ. 5-Lipoxygenase-activating protein (FLAP). J Lipid Mediat Cell Signal 1995;12:185-94.
36. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med 1998;157:S227-32. (Pubitemid 28304148)
37. Rennard SI, Jaurand MC, Bignon J, Kawanami O, Ferrans VJ, Davidson J, et al. Role of pleural mesothelial cells in the production of the submesothelial connective tissue matrix of lung. Am Rev Respir Dis 1984;130:267-74. (Pubitemid 14055816)
38. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002;13:413-21.
39. Singh VK, Yadav VS. Role of cytokines and growth factors in radioprotection. Exp Mol Pathol 2005;78:156-69. (Pubitemid 40248799)
40. Berg DJ, Zhang J, Lauricella DM, Moore SA. Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J Immunol 2001;166:2674-80. (Pubitemid 32173507)
41. Szumiel I. Intrinsic radiation sensitivity: cellular signaling is the key. Radiat Res 2008;169:249-58. (Pubitemid 351521760)
42. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, Einhorn N, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol 2003;42:357-65. (Pubitemid 37193830)
43. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134-42.
44. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 1997;151:317-22.
45. Knight D. Epithelium-fibroblast interactions in response to airway inflammation. Immunol Cell Biol 2001;79:160-4. (Pubitemid 32281088)
46. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001;22:199-204. (Pubitemid 32673659)
47. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4:529-36. (Pubitemid 38351709)
48. Trott KR, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother Oncol 1999;51:197-203. (Pubitemid 29305702)
49. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006;6:702-13. (Pubitemid 44286002)
50. Jaal J, Dorr W. Early and long-term effects of radiation on intercellular adhesion molecule 1 (ICAM-1) expression in mouse urinary bladder endothelium. Int J Radiat Biol 2005;81:387-95. (Pubitemid 41117009)
51. Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol 1999;53: 37-44.
52. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park) 2002;16:217-26. 29, discussion 30-2.
53. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-84. (Pubitemid 38063698)
54. Chi YS, Jong HG, Son KH, Chang HW, Kang SS, Kim HP. Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem Pharmacol 2001;62:1185-91. (Pubitemid 33055622)
55. Yang YM, Hyun JW, Sung MS, Chung HS, Kim BK, Paik WH, et al. The cytotoxicity of psoralidin from Psoralea corylifolia. Planta Med 1996;62:353-4.
56. Mar W, Je KH, Seo EK. Cytotoxic constituents of Psoralea corylifolia. Arch Pharm Res 2001;24:211-3.
57. Pahari P, Rohr J. Total synthesis of psoralidin, an anticancer natural product. J Org Chem 2009;74:2750-4.
58. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60. (Pubitemid 27010118)